Cancer Drug Resistance represents a point on the path of the long journey toward understanding the complex interactions between host, tumor and cytotoxic or immunomodulatory agents. It addresses the resistance of solid tumors to anticancer therapeutics by considering mechanisms that involve alterations in genetics and epigenetics, cellular biochemistry, properties related to physiology of the solid tumor mass and alterations in host metabolic and immune status induced by the presence of malignant disease.